Jim Cramer makes comments on Exxon Mobil Corp. (NYSE: XOM), says the stock is not a sell at this level.
JP Morgan Adds DivX To Its Focus List, $30 Price Target
Analysts Comment on Motorola (MOT) Following Warning
JP Morgan adds Divx (DIVX) to their Focus List
Cramer's Top Growth Stocks are CSCO, AAPL, NYX
McDonald’s (MCD) Could Sell Latin American Operations - Analyst
Jim Cramer Makes Positive Comments on MO, CELG and the Tech Sector
S&P Equity Research Reiterates Sell on Haverty Furniture (HVT)
eBay (Nasdaq: EBAY) fee increases are positive for earnings says Bear Stearns - Bloomberg
S&P Equity Research Reiterates a Sell on Hot Topic (HOTT)
Merrill Lynch Raises Its Price Target on Celgene (CELG) to $73
Think Equity names On2 Technologies Inc. (ONT) at Top Pick for 2007
JP Morgan adds PepsiCo (PEP) to their Focus List
Piper Jaffray Says Apple (AAPL) Product Announcements Could Include iTV, a new iPod, and the iPhone
Piper Jaffray names Array BioPharma (ARRY) a new Top Pick for 2007
Cramer's Top Value Stocks are HAL, GS and MO
Stifel Nicolaus Comments on Management Change at Home Depot (HD)
StarMine's top POSITIVE/NEGATIVE predicted earnings surprises for Q4
Stifel Nicolaus Sees January Rebound in Sirius Satellite (SIRI) Shares
Analysts Comment on Sirius (SIRI) Following Sub Numbers and Cash Flow Guidance
Negative Analyst Comments on AMD
Soleil Securities raises its price target on Apple (AAPL) to $100
Jefferies & Co Names Taser Int'l (TASR) as Top Pick of 2007
Stifel Nicolaus added Google Inc. (GOOG) to its Select List
Piper Jaffray called Google Inc. (GOOG) a Top Pick for 2007
WR Hambrecht Comments on Altair Nanotechnologies (ALTI), Awaiting Big Order
CNBC Guest Takes Negative Tone on Results of Apple's (AAPL) Option Review
Piper Jaffray Comments on Apple (AAPL) Option Grant Update
UBS Raises Price Target on Huron Consulting (HURN)
Stifel Nicolaus Sees Possibility of Bidding War for Alltel (AT)
Stifel Nicolaus raises its price target on Pilgrim's Pride (PPC) to $36
Thomas Weisel Said Checks Show Strong Holiday Demand for Apple's (AAPL) Intel-based Macs and iPods
ThinkEquity Doesn't Sees China Deal for Dell (DELL)
Soleil Maintains Positive Stance on Blockbuster (BBI)
JP Morgan reiterates its Overweight rating on Apple Computer (AAPL) - Bloomberg
S&P Equity Research Reiterates a Buy Rating on Apple Computer (AAPL)
Jefferies Analyst Comments on USG Corp (USG)
UBS Maintains Positive Stance on Rockwell Collins (COL)
S&P Equity Research Reiterates Buy Rating on Cameron Int'l (CAM)
Acme Pocket (APKT) is Trading Higher After Comments by Jim Cramer
Goldman Sachs Adds Lockheed Martin (LMT) to Americas Conviction Buy List
Wachovia Highlights Costco (COST) As Their Top Pick for 2007
Jim Cramer makes comments on: AA, BHP, TXN, CAT, HON, IFF & MO
S&P Equity Research Reiterates Buy Rating on Walgreen (WAG)
Analysts Comment on Micron (MU) Following Results
Analysts Comment on QUALCOMM (QCOM) After Lowered EPS Guidance
Stifel Nicolaus Analyst Comments on Shuffle Master (SHFL)
Morgan Joseph Reiterates Buy Rating on Sonic Corp (SONC)
Earlier today, Brean Murray raised their price target on HDTV maker Syntax-Brillian Corporation (Nasdaq: BRLC) from $14 to $18 and raised estimates for 2QFY07 (December) and the next six subsequent quarters. The firm said their move was based on research revealing better-than-expected shipments in both North America and Asia, continued wins into the largest retailers and strong gross margins.
Commenting on strong orders Analyst Michael H.V. Tieu said, "Our research has uncovered that at least two mega North American retailers will begin rolling out Olevia TVs nationwide in 1HCY07, while incumbent retailers such as Circuit City and others are issuing multiple reorders to meet rising demand."
Commenting on strong margins Tieu said, "Despite a declining unit price for LCD TVs, which could lead some to speculate that gross margins may get squeezed, a confluence of factors suggests gross margins will likely exceed management’s guidance of 15-17% for 2QFY07."
The firm maintained their Buy rating and reitreated BRLC as one of their top picks for 2007.
Shares of Syntax-Brillian are 10.4% higher to $9.97 in mid-day action. Stifel Nicolaus Comments on Hansen Natural (HANS) Deal with Pantry
Stifel Nicolaus comments on Hansen (Nasdaq: HANS). The firm said according to Beverage Business Insights, Pantry Inc. (Nasdaq: PTRY) puts Monster and other Hansen brands into the company's approximately 1,500 stores in the Southeast U.S. The firm said the Anheuser-Busch relationship was the contributing factor for the win.
The firm continues to estimate 43% energy drink volume growth for Hansen in 2007.
The firm reiterates their Buy rating and $42 price target. Longbow Research's Top Picks for 07 are HANS, CCK, BLL; Short COT
Longbow Research Top Picks for 2007 are Hansen Natural (Nasdaq: HANS), Crown Holdings (NYSE: CCK) and Ball (NYSE: BLL) on the long side. Cott (NYSE: COT) on the short side.
For HANS the firm said, "We see significant upside to our current 2007 estimate based on potentially higher than expected energy drink category demand growth, same store and distribution gains for Monster, rate price increases and on-premise channel/Europe penetration."
For CCK the firm said, "Key drivers to 2007 earnings/FCF include a global recovery in bev can contract pricing, added specialty can capacity and robust emerging market growth."
For BLL the firm said, "Key drivers to 2007 earnings include a global recovery in bev can contract pricing, startup of BLL's German bev can plant, internal cost savings, acquisition synergies and an Aerospace segment recovery."
For COT the firm said, "Key issues facing COT in 2007 include metal can costs, lack of pricing power, pressure on soft drink category demand, Albertson's store closings and limited value brand penetration. Importantly, a reasonable average LME spot price assumption of $1.10 places $0.45-$0.50 of earnings risk on COT in 2007 (versus our current $0.95 assumption)." Jefferies & Co Names Top Biotech Picks for 2007 - AMAG, CYPB and MBRX
Jefferies & Co analyst, Adam A. Walsh, names Top Biotech Picks for 2007 - AMAG, CYPB and MBRX.
Jefferies analyst speaks on Advanced Magnetics Inc. (Nasdaq: AMAG), "Despite a phenomenal run in 2006 (up 439% in 2006), we expect AMAG to continue to post solid gains in 2007 as multiple ferumoxytol milestones are on tap and the prospect of a take-out by a larger player looms."
Jefferies analyst speaks on Cypress Biosciences (Nasdaq: CYPB), "We believe CYPB represents a highly attractive risk/reward opportunity at current levels and recommend the shares based on 1) limited downside, 2) lead drug addresses $1 billion+ market opportunity (FMS)...5) our industry contacts suggest that the FDA may be lowering the bar on the requirements for FDA approval of drugs for FMS."
Jefferies analyst speaks on Metabasis Therapeutics Inc. (Nasdaq: MBRX), "We view MBRX shares as an attractive investment opportunity, based on its proprietary and partnered pipeline strength, attractive valuation, multiple upcoming milestones, large targeted market opportunities, and strong management team." JP Morgan names Medco (MHS) its Top Pick for 2007, Adds to Focus List
